Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population

Metabolism: Clinical and Experimental

Volumn 57, Issue 8, 2008, Pages 1130-1134

  Jalovaara, Kirsti ^a,b   Santaniemi, Merja ^a,c   Timonen, Markku ^a   Jokelainen, Jari ^a,c   Kesäniemi, Y Antero ^a,c   Ukkola, Olavi ^a,c   Keinänen Kiukaanniemi, Sirkka ^a,b   Rajala, Ulla ^a  

^a UNIVERSITY OF OULU   (Finland)

^b Oulu Health Center   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; LIPID;

ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADIPONECTIN; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 47249099737     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.03.019     Document Type: Article

References (38)

1. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor apM1. Biochem Biophys Res Commun 221 (1996) 286-289
2. Ukkola O., and Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities?. J Mol Med 80 (2002) 696-702
3. Hulte J., Hulten L.M., and Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 52 (2003) 1612-1614
4. Ukkola O., Santaniemi M., Rankinen T., Leon A.S., Skinner J.S., Wilmore J.H., et al. Adiponectin polymorphisms, adiposity and insulin metabolism: HERITAGE family study and Oulu diabetic study. Ann Med 37 (2005) 141-150
5. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
6. Lafontan M., and Viguerie N. Role of adipokines in the control of energy metabolism: focus on adiponectin. Review. Curr Opin Pharmacol 6 (2006) 580-585
7. Lara-Castro C., Fu Y., Chung B.H., and Garvey T. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol (2007)
8. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxial decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
9. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
10. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
11. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68 (2004) 975-981
12. Salmenniemi U., Ruotsalainen E., Pihlajamäki J., Vauhkonen I., Kainulainen S., Punnonen K., et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110 (2004) 3842-3848
13. Nilsson P., Engström G., Hedblad B., Frystyk J., Persson M.M., Berglund G., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 26 (2006) 2758-2762
14. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
15. Daimon M., Oizumi T., Saitoh T., Kameda W., Hirata A., Yamaguchi H., et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 26 (2003) 2015-2020
16. Snehalatha C., Mukesh B., Simon M., Viswanathan V., Haffner S.M., and Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26 (2003) 3226-3229
17. Duncan B.B., Schmidt M.I., Pankow J.S., Bang H., Couper D., Ballantyne C.M., et al. Adiponectin and the development of type 2 diabetes. Diabetes 53 (2004) 2473-2478
18. Yamamoto Y., Hirose H., Saito I., Tomita M., Taniyama M., Matsubara K., et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci 103 (2002) 137-142
19. Nakashima R., Kamei N., Yamane K., Nakanishi S., Nakashima A., and Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 91 (2006) 3873-3877
20. Vendramiini M.F., Ferreira S.R.G., Gimeno S.G.A., Kasamatsu T.S., Miranda W.L., and Moises R.S. Plasma adiponectin levels and incident glucose tolerance in Japanese-Brazilians: a seven-year follow-up study. Diabetes Res Clin Pract 73 (2006) 304-309
21. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 (2003) 226-228
22. Fumeron F., Aubert R., Siddiq A., Betoulle D., Pean F., Hadjadj S., et al., for the Epidemiologic Data on the Insulin Resistance Syndrome (DESIR) Study Group. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycaemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 53 (2004) 1150-1157
23. Koenig W., Khuseyinova N., Baumert J., Meisinger C., and Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men. J Am Coll Cardiol 48 (2006) 1369-1377
24. Schwarz P.E.H., Towers G.W., Fischer S., Govindarajalu S., Schulze J., Bornstein S.R., et al. Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter. Diabetes Care 29 (2006) 1645-1650
25. Snijder M.B., Heine R.J., Seidell J.C., Bouter L.M., Stehouwer C.D.A., Nijpels G., et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study. Diabetes Care 29 (2006) 2498-2503
26. Wannamethee G.S., Lowe G.D.O., Rumley A., Cherry L., Whincup P.H., and Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 30 (2007) 1200-1205
27. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva, World Health Org.; 1999 [publ. no. WHO/NCD/NCS/99.2].
28. Rajala U., Koskela P., and Keinänen-Kiukaanniemi S. Hyperglycemia as a risk factor of mortality in a middle-aged Finnish population. J Clin Epidemiol 54 (2001) 470-474
29. Rajala U., Laakso M., Päivänsalo M., Pelkonen O., Suramo I., and Keinänen-Kiukaanniemi S. Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab 87 (2002) 5092-5097
30. World Health Organization. Diabetes mellitus: report of a WHO study group. Tech. Rep. Ser., no. 727 (1985), World Health Organization, Geneva
31. Rajala U., Qiao Q., Laakso M., and Keinänen-Kiukaanniemi S. Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract 50 (2000) 231-239
32. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to a biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
33. Santaniemi M., Kesäniemi A.Y., and Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 155 (2006) 1-7
34. Matsushita K., Yatsuya H., Tamakoshi K., Wada K., Otsuka R., Takefuji S., et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26 (2006) 871-876
35. Winer J.C., Zern T.L., Taksali S.E., Dziura J., Cali A.M.G., Wollschlager M., et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab 91 (2006) 4415-4423
36. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
37. Alberti K.G.M.M., et al. The metabolic syndrome: a new world-wide definition. Lancet 366 (2005) 1059-1062
38. Peake P.W., Kriketos A.D., Campbell L.V., Shen Y., and Charlesworth J.A. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur J Endocrinol 153 (2005) 409-417